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Background: Most adult-onset sporadic ataxias are unexplained, and the claim that many of these may be a result
of gluten sensitivity has led to uncertainty as to whether to test for anti-gliadin antibodies (αGAb) and, if present,
whether to recommend a gluten-free diet or continue searching for other causes of ataxia. This uncertainty arises in
part from the frequency of αGAb in the population (about 1 in 10), but recent work delineating transglutaminase 6
as the target antigen in gluten ataxia has clarified the situation somewhat. Our aim was to determine whether there
is molecular mimicry between cerebellar Purkinje cell antigens and gluten in subjects selected for recent diagnosis
of CD rather than for ataxia.
Results: High titre αGAb sera from 11 newly-diagnosed CD patients and normal sera from 10 healthy controls were
used to detect cross-reacting antibodies to cerebellar and cerebral cortex antigens in mouse, monkey and human
tissue. None of the CD patients displayed ataxia. Mouse and human cerebellar and cerebral cortex extracts were
analysed by Western blot probed with CD and control sera. Immunofluorescence microscopy was used on mouse
and monkey cerebellar sections immunostained with CD and control sera to detect cross-reacting IgG antibodies.
Western blot analysis of cerebellar and cerebral cortex extracts probed with CD sera did not demonstrate any
specific immunoreactivity unique to the cerebellum. An identical twin pair with CD produced different patterns of
reactivity. Immunofluorescence staining of mouse and monkey cerebellar sections showed most control and CD
sera reacted non-specifically, with the exception of two CD and one control sera, each having a unique staining
pattern.
Conclusions: CD patient sera with high titre αGAb do not detect a common Purkinje cell or cerebellar-specific
epitope. The pattern of reactivity is not solely dependent on genetic background.
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Classical coeliac disease (CD) is a chronic immune-
mediated enteropathy, triggered by the ingestion of
gluten proteins from wheat, rye and barley in genetic-
ally susceptible individuals positive for HLA DQ2 and/
or DQ8, and resulting in malabsorption [1,2]. Non-
classical CD is increasingly recognised, and consists of
enteropathy without malabsorption [2]. Gliadin is a
moiety of wheat prolamins, and IgA anti-gliadin anti-
bodies have been used to support the diagnosis of CD.
They are, however, relatively non-specific, being found
in about 1 in 10 individuals in Anglo populations [3],* Correspondence: elsdon.storey@monash.edu
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unless otherwise stated.compared with a prevalence of classical plus non-classical
CD of about 1 in 100 in the USA [4]. Recent Australian
figures are similar, showing αGAb IgG in 17% and αGAb
IgA in 7%, compared with an estimated prevalence of
coeliac disease 1.6% in a random community sample [5].
Gliadin is deamidated in the gut wall by tissue trans-
glutamidase (transglutamidase-2 – TG2) and this deami-
dated protein stimulates a cellular immune response in
HLA DQ2/8 individuals [6]. Antibodies to deamidated
gliadin peptide, to TG2, and anti-endomysial antibodies
are now used to support the diagnosis of CD, being
much more specific than anti-gliadin antibodies [2].
However, diagnosis of CD in adults and most children
still requires confirmatory small bowel biopsy [2,7].
An area of recent interest has been the relationship be-
tween gluten sensitivity and (otherwise) idiopathic sporadictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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(otherwise) idiopathic sporadic ataxia with anti-gliadin anti-
bodies [2]. The presentation is usually as a pure ataxia of
insidious onset with or without an accompanying sensory-
motor, length-dependent neuropathy, although a subacute
course, myoclonus, opsoclonus and palatal tremor are all
described [1].
Most but not all studies have shown a high prevalence
of gluten sensitivity in sporadic ataxia patients eg. [3,6].
There is only partial overlap with CD, with only about
one third having enteropathy, and less than 40% having
anti-TG2 antibodies [1]. Conversely, ataxia and/or neur-
opathy are found in about 6-10% of CD patients [7,8].
This incomplete overlap has recently been illuminated
by the finding that antibodies to TG-6 (especially IgG)
are found in about 75% of patients with GA [9]. TG-6 is
a predominantly neural isoform of transglutaminase, and
is found extracellularly as well as intracellularly [10].
The extracellular location implies that it might be a
pathogenic target of humoral autoimmunity, and indeed
an anti-TG2 antibody cross-reactive with TG-3 and
TG-6 induced transient ataxia in mice when injected
intraventricularly [11]. Moreover, a mutation in TG-6
has been reported to cause dominantly-inherited SCA
35 in three Chinese families with three different het-
erozygous mutations [12,13], emphasising the potential
for TG-6 as a pathogenic target in GA.
GA does remain somewhat contentious, however. In
part, this may arise from the use of the relatively non-
specific anti-gliadin antibodies to define the syndrome.
Furthermore, some studies have failed to show an in-
creased rate of anti-gliadin antibodies in sporadic ataxia
[14]. Moreover, patients with hereditary ataxias have been
reported to have higher rates of anti-gliadin positivity than
healthy controls [15]. This raises the possibility that anti-
gliadin antibodies might be epiphenomena, being gener-
ated against cross-reactive cerebellar epitopes unmasked
by cerebellar damage from other causes, in genetically-
predisposed individuals. It is also possible that cerebellar
damage from other causes might expose neo-epitopes on
cerebellar TG-6 itself.
This study aimed to determine whether cerebellar epitopes
are recognised by sera from newly-diagnosed CD patients
with high-titre anti-gliadin antibodies (αGAb), regardless of
the presence or absence of ataxia. This cross-reactivity would
support the hypothesis that αGAbs cross-react with cerebel-
lar antigens, and indeed also the converse hypothesis that
GA may sometimes be diagnosed in patients in whom
cerebellar neo-epitopes are exposed by cerebellar dam-
age from non-gluten sensitivity causes, resulting in
antibodies cross-reactive with gliadin. We postulated
that an epitope present in cerebellum but not cere-
brum would be identified by sera from a subset of CD
patients, but not from control subjects.Results
Newly diagnosed CD patients have high titre gliadin
antibodies
Serum from newly diagnosed CD patients and healthy
controls was tested by ELISA for the presence of αGAb.
CD patients had high αGAb titres, with mean titres of 1
in 2.15 × 104 (range <1 in 1.0 × 103 to 1 in 1.28 × 105)
for IgA (Figure 1a), 1 in 8.4 × 104 (range <1 in 1.6 × 104
to 1 in 2.6 × 105) for IgG (Figure 1b), and 1 in 1.1 × 105
(range <1 in 8.0 × 103 to 1 in 2.6 × 105) for IgA,G and
M together (Figure 1c). All 11 (100%) CD patient αGAb
IgG titres were >2 SD above the mean of the control
titre, compared with only 6/11 (55%) for IgA and 9/11
(82%) for IgA,G and M combined. Patient CD7 had the
highest titre of αGAb for all Ig isotypes tested. A pair of
identical twins (CD4 and CD5) were also included in
this study and their titres are identified in Figure 1a-c
with a triangle symbol. Western blot analysis of wheat
gliadin extract probed with patient serum (1:250 to 1:1000
dilutions) for αGAb IgG antibodies (Figure 1d) showed a
heterogeneous reactivity profile between the CD patients
and very little reactivity of serum from the healthy con-
trols. The identical twin patients, CD4 and CD5, had simi-
lar IgG immunoreactivity to gliadin.
Western blot analysis did not reveal a CD-specific
cross-reacting cerebellar epitope mouse cerebellum
Sera from adults with CD and healthy controls were
screened for autoantibodies to total protein extracts from
adult mouse cerebellum and cerebral cortex by Western
blot. Total protein extracts of mouse cerebellum (Figure 2a)
and cerebral cortex (Figure 2b) were separated by SDS-
PAGE and probed for cross-reacting IgG antibodies. Both
CD and healthy control samples produced a complex im-
munoreactive banding profile. It is notable that CD pa-
tients 4 and 5 – identical twins diagnosed within a week of
each other – had a similar pattern of gliadin immunoreac-
tivity (Figure 1d), but quite different patterns of cerebellar
immunoreactivity. To identify any immunoreactive targets
that were unique to mouse cerebellum as distinct from
mouse cerebrum, Western blots of mouse cerebellum and
cerebral cortex were compared to each other (Figure 2).
CD patients 2, 4, and 8 had autoantibodies directed to
cerebellar proteins not detected by their sera in the cere-
bral cortex. CD patient 8 detected a single unique protein
of 185 kDa. CD patients 2, 4 and 7 detected multiple tar-
gets that were unique to cerebellum or only faintly de-
tected in the cerebral cortex; CD2 detected targets of 40,
55, 58, 70 and 72 kDa; CD4 detected two bands of 20 kDa
and 120 kDa; CD7 detected a doublet of 47–50 kDa. The
only uniquely cerebellar immunoreactive proteins that
were found only in CD patients and not in healthy
controls were a 20 kDa protein detected solely in CD4,
a 55 kDa protein detected by CD2 and a 185 kDa
Figure 1 CD patients have high titres of anti-gliadin antibodies. The reciprocal titre of anti-gliadin (a) IgA, (b) IgG and (c) IgA,G,M-class antibodies
in 11 CD and 9 control subjects was measured by an in-house gliadin ELISA. Error bars represent mean and standard deviation and the horizontal dotted
lines indicate 2 standard deviations from the control mean titre. Triangle symbol within graphs denotes twin sibling CD patients. (d) Western blot of
wheat gliadin extract probed with serum from CD and control patients for IgG antibodies specific to gliadin, and a rabbit anti-gliadin antibody (SG). The
CD patients had a strong yet heterogeneous pattern of immunoreactivity to gliadin.
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immunoreactive profile of CD and control sera to mouse
cerebellum did not identify proteins that were common to
CD patients and absent in healthy controls. Table 1 sum-
marises the unique immunoreactive bands. TG6 has two
isoforms of 70–71 and 79 kDa [10] but was detected as a
faint 60 kDa band in the cerebral cortex only, on Western
blot (Figure 2b). The TG6 antibody detected additional
bands of 30–32 and >260 kDa in cerebral cortex and
bands of 170 kDa and >260 kDa in the cerebellum
(Figure 2a and b). None matched the bands detected
by the CD patient sera. There was minimal cross-reaction
between rabbit polyclonal antigliadin antibody (Sigma)
and cerebellar antigens, and none at the Mr’s of TG6.
Additional Western blotting was performed on total pro-
tein extracts of human cerebellum (Figure 3a) and cerebral
cortex (Figure 3b) for the presence of autoantibodies in
CD patient serum. Similarly to the mouse tissue Westerns,both CD and healthy control samples produced a complex
heterogeneous immunoreactive banding profile. Once
again, CD4 and 5 – identical twins – produced differ-
ent patterns of immunoreactivity. Contaminating IgG
heavy chain of 55 kDa in both tissue sample extracts
was detected by the goat anti-human IgG secondary
antibody. Cerebellar-specific immunoreactive proteins
were identified in CD patients 1, 4, 8 and 10. Serum
from patient CD1 detected a protein of Mr40 kDa, that
from CD4 detected faintly a 130 kDa protein, that
from CD8 a 34 kDa protein and that from CD10 de-
tected 34 and 135 kDa proteins. The 135 kDa protein
detected by CD10 is detected in all other sera but
much less intensely (Figure 3a). The bands detected by
CD 4 and 8 also appear to be present in Western blots
of some healthy control sera. Comparison of CD and
control immunoreactive profiles to human cerebellar
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Figure 2 CD patient serum has a heterogeneous immunoreactivity to mouse brain protein extracts. Western blots of mouse brain protein
extracts probed for cross-reacting antibodies with CD and control patient serum. Mouse cerebellar (a) and cerebral cortex (b) total protein extracts
were probed with CD and control serum for IgG cross-reacting antibodies. Both CD and control serum identified numerous bands of varying size and
intensity. The circled bands indicate immunoreactive proteins that are unique to the cerebellum, and identified by CD but not control serum. Bands
indicated by parenthesis have markedly less intensity or cerebral cortex Western. CD4 and 5 are the identical twins. TG6 rabbit polyclonal
did not detect either the long 79 kDa or short 71 kDa isoform on the two brain regions tested. However, the TG6 antibody detected a band
of 170 kDa in the cerebellum and bands of 30–32, 60 and >260 kDa in cerebral cortex extracts. T = anti-TG6 antibody and SG = rabbit
anti-gliadin antibody.
Tarlac et al. Cerebellum & Ataxias 2014, 1:18 Page 4 of 9
http://www.cerebellumandataxias.com/content/1/1/18several CD patients but absent in healthy controls, and
revealed a different pattern from that seen with mouse
cerebellar extracts (Table 1). The TG6 antibody was
unable to detect either the 71 or the 79 kDa isoforms
in the 500 ug human cerebral cortex total protein ex-
tract loaded on the gel (Figure 3b). The TG6 antibody
only detected a high MW band of >260 kDa. The TG6
Ab was tested on a separate Western blot of mouse
and human cerebellar total protein extracts loaded at
the same protein concentration but without preboilingTable 1 Summary of main findings for Western blotting and i
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CD3 -ive -ive -ive
CD4* 20 & 120 20 130
CD5* -ive -ive -ive
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CD8 185 185 34
CD9 -ive -ive -ive
CD10 -ive -ive 34 & 130
CD11 -ive -ive -ive
ns = non-significant, −ive = no unique band on Western blot, Ins = interneuron, * = iand was found to detect very faint bands of 64, 35 and
32 kDa in mouse and 66 and 32 kDa in human (data
not shown).
CD patient serum does not react to a common cerebellar
antigen in mouse or monkey sections
Mouse cerebellar sections were immunostained with CD
patient sera for the presence of cerebellar autoanti-
bodies. Background staining, which consisted of varying
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Figure 3 CD patient serum binds to human cerebellar and cerebral cortex protein extracts in a heterogeneous manner. Western blots of
human brain protein extracts were probed for cross-reacting antibodies with CD and control patient serum. Normal human cerebellar (a) and
cerebral cortex extracts (b) were probed with patient serum for cross-reacting IgG antibodies. CD and control patient serum bound to numerous
bands with varying intensity. The circled bands indicate immunoreactive proteins that are unique to the cerebellum immunoreactive to CD but
not control serum. Non-identical twins, CD4 and CD5, have immunoreactive patterns different from each other. The arrow heads at ~52 kDa in
both panels indicate IgG heavy chain detected by the secondary rabbit anti-human IgG Ab. The rabbit TG6 antibody only detected a >260 kDa
band in the cerebral cortex (b). T = anti-TG6 antibody.
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ondary Ab only (data not shown). Three different positive
controls were also tested: anti-calbindin immunostaining
(Figure 4a) showed the normal morphology of the cere-
bellum – specifically PC somata and dendrites; anti-
Hu autoimmune serum bound to the nuclei of PCs and
granular cell layer neurons as expected [16] (Figure 4b);
anti-Yo autoimmune serum produced coarse granular
immunostaining of the PC cytoplasm, as previously re-
ported [17] (Figure 4c). Control human serum from
control subjects 1–10 had the same pattern of immu-
noreactivity as secondary antibody alone, but with a
slight increase in PC, molecular layer and granular cell
layer immunoreactivity (Figure 4d and 4e). With the ex-
ception of patient CD10, the remaining ten CD patients
had a similar pattern of immunoreactivity to the healthy
controls (Figure 4f), with the PCs showing diffuse immu-
noreactivity and both molecular and granular cell layers
immunostaining to varying degrees. Sera from three CD
patients (CD2, 7, 11) and one control (C4) appeared to
immunoreact to a subset of interneurons (Figure 4g). A
single CD patient, CD10, had a different pattern of immu-
noreactivity from the other CD patients; the serum immu-
nostained nucleoli of PCs, molecular and granular layer
neurons (Figure 4h).
Monkey cerebellar sections were also used to detect
autoantibodies to cerebellar antigens in CD serum. Anti-
Hu autoimmune serum, used as a positive control, reacted
with the nucleus of PC and granular cell layer neurons, as
expected (Figure 5a). The anti-Yo autoimmune serum
positive control produced the typical coarse granularimmunostaining of the PCs only (Figure 5b). Most healthy
controls showed slight immunoreactivity to PCs and pre-
sumed endothelial cells (Figure 5c and 5d). Serum from a
single healthy control (C9) showed punctate immunoreac-
tivity to the nuclei of PCs, granular cells and molecular
layer cells (Figure 5e), which was different from that of
anti-Hu (Figure 5a) and patient CD10 (Figure 5g). Figure 5f
shows the typical immunoreactivity pattern of nine of the
eleven CD patients, with slight immunostaining of PCs
and the granular cell layer, as well as presumed endothelial
cells. Sera from two patients, CD10 (Figure 5g) and CD11
(Figure 5h), each reacted differently to the cerebellum
than those from the other nine CD patients. As in the
mouse cerebellum (Figure 4h), CD10 showed punctate
immunoreactivity to the nuclei of all cells of the cerebel-
lum (Figure 5g). Serum from this CD patient also reacted
to the nuclei of all cells in rat intestine and liver tissue sec-
tions (data not shown). Serum from patient CD11 showed
a strong basket-like immunoreactivity pattern surrounding
the PCs (Figure 5h), in contradistinction to the pattern
seen in mice (Figure 4g). As noted, CD11 patient sera had
basket-like immunoreactivity surrounding the PCs which
resembled that of anti-GAD antibodies [18]. We tested 9/
11 CD patients’ sera for anti-GAD, including patient CD
11, and only patient CD9 was positive with a titre of >2,000
U/ml. The remaining eight had a titre of <0.6 U/ml
(reference range <5 U/ml).
With respect to those CD and control sera not showing
a distinct pattern of immunoreactivity, a blinded observer
failed to distinguish between the intensity or pattern of
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Figure 4 Mouse cerebellar sections were immunostained with control and CD patient serum for cross-reacting IgG antibodies.
Calbindin staining (a) was used as a control to identify PC somata and dendrites. Anti-Hu human auto-immune serum positive control
(b) demonstrates nuclear immunoreactivity of PCs and granular cells. (Light- blue nuclei indicate co-localisation with DAPI). Anti-Yo
auto-immune positive control (c) immunostained the cytoplasm of PCs in a granular pattern. Typical control patient immunostaining pattern is
demonstrated by serum from C1 (d) and C5 (e) showing non-specific immunostaining of PCs and non-specific granular layer staining. Representative
images of typical CD patient serum immunostaining PCs are shown with CD4 (f) and CD11 (g). CD11 (g) also demonstrated immunoreactivity to a
subset of interneurons. Serum from patient CD10 (h) had unique immunoreactivity to all cerebellar nucleoli as well as the cytoplasm of PCs. Arrows
indicate PCs. Asterisk indicates interneurons. Scale bar =100 μm.
Tarlac et al. Cerebellum & Ataxias 2014, 1:18 Page 6 of 9
http://www.cerebellumandataxias.com/content/1/1/18Discussion
“Gluten ataxia”, marked by anti-gliadin antibody positivity
[2] and possibly relating to anti-tissue transglutaminase-6
antibodies [9], has been advanced as the most common
cause of sporadic progressive ataxia [3]. We sought to de-
termine whether there was a common antigen, found in
cerebellum but not cerebrum, presumably recognised by
anti-gliadin and/or anti-tissue transglutaminase antibodies,
in newly diagnosed patients with coeliac disease.
Newly-diagnosed subjects were chosen as their antibody
titres were likely to be high, and indeed this was the case.
Gliadin is, however, antigenically complex, and the CD
subjects demonstrated a broad array of patterns of anti-
gliadin reactivity (Figure 1d); many bands are not common
across all patients and several are unique. If the relevant
cerebellar antigen(s) in gluten ataxia were pathogenic tar-
get(s) via cross-reactivity of various anti-gliadin antibodies,
it would therefore not be surprising that we found no uni-
form pattern of cerebellar antigen recognition on Western
blotting or immunohistochemistry.
It remains possible that cross-reaction between gliadin
and cerebellar antigens involves a gliadin and cerebellar
epitope not recognised in our CD subjects, and perhaps
unrelated to gut disease [1]. Thus, perhaps only a subset
of patients with CD develop antibodies to a uniquegliadin epitope that cross-reacts with an accessible
(cell surface) cerebellar epitope, and are themselves
pathogenic. In indirect support of this, our results il-
lustrate the heterogeneous nature of anti-gliadin anti-
bodies. Tissue transglutaminase-6 has been proposed
as the target cerebellar antigen in this regard, being
found extracellularly as well as intracellularly in the
cerebellum [10]. This is conceivable despite our results –
all our CD subjects were selected on the basis of gut ra-
ther than of cerebellar disease (although ataxia was not an
exclusion criterion), whereas only 6-11% of CD patients
have clinically evident ataxia and/or neuropathy [7,19].
Any such antigen would presumably need to be expressed
in cerebellum but not cerebrum, as gluten ataxia is typic-
ally a pure ataxic syndrome, rather than a heterogeneous
one also encompassing limbic encephalitis and/or myelitis
as is seen, for example, with anti-Hu disease. It is worth
noting, however, that none of the CD sera detected anti-
gens matching the Mr of that identified by the anti-tissue
transglutaminase-6 antibody. (More direct testing of CD
sera against purified anti-tissue transglutaminase-6 was
not performed due to lack of availability of the latter).
Another possibility is that patients susceptible to glu-
ten ataxia may develop pathogenic anticerebellar anti-
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Figure 5 Cerebellar monkey brain sections were stained with serum from control and CD patients for cross-reacting IgG antibodies.
Anti-Hu human auto-immune serum positive control (a) immunostained the nuclei of PCs and granular cells. Anti-Yo (b) auto-immune serum
showed slight immunoreactivity to PC cytoplasm in a granular pattern. Most non-CD control serum showed immunoreactivity of PCs and endothelial
cells as demonstrated by patients C7 (c) and C8 (d). Control patient C9 (e) differed from the other controls with punctate immunoreactivity to the
nucleus of PCs and granule cells. A representative image of CD patient serum with light immunoreactivity of PCs is shown in panel f (CD5).
Serum from patient CD10 (g) stained the nucleoli of all cells of the cerebellum including PCs. CD11 patient serum (h) showed basket-like
immmunostaining surrounding the PCs. Arrows indicate PCs and asterisk indicates endothelial staining. Scale bar =50 μm.
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adin. Our study would be unable to confirm or refute
this possibility, although the lack of a common CD-
specific band in Western blots of lysed cerebellar tissue
would argue against it. The increased prevalence of anti-
gliadin antibodies in those symptomatic with hereditary
ataxias [15] is consistent with this otherwise unlikely-
seeming hypothesis. Against this is our failure to find a
common cerebellar antigen on Western blotting with
CD sera, or even a consistent pattern of immunoreactivity
on immunohistochemistry, both procedures that should
uncover cerebellar epitopes concealed in normal live
individuals.
Several other points are worth noting. First, the pat-
tern of immunorecognition of cerebellar-only and of
cerebral antigens on Western blotting is appreciably dif-
ferent in mouse compared with that in humans. This
suggests that mouse models of passively transferred glu-
ten ataxia [11] may not necessarily be appropriate, and
that this difference may have contributed to our previ-
ous failure to produce cerebellar damage by active im-
munisation in HLA-transgenic mice [20]. Second, the
anti-neural patterns of immunoreactivity in the identical
twin pair on Western blotting were quite different, des-
pite an apparently identical pattern of antigliadin activ-
ity, arguing that response to a cerebellar antigen (suchas anti-tissue transglutaminase-6) in gluten ataxia is not
solely dependent on genetic predisposition. Lastly, sera
from one CD subject (11) showed immunoreactivity sur-
rounding PCs in a basket pattern; it seems from this that
even antibodies recognising possibly extracellular cere-
bellar antigens do not necessarily result in ataxia. The
basket-like pattern surrounding PCs was not due to
anti-GAD antibodies which were only detected in the
sera of patient CD 9.
Conclusion
In summary, the pattern of antigen reactivity in CD is
complex and variable for both gliadin and for neural
(and specifically for cerebellar) antigens, and is not solely
genetically determined. The pattern of immunoreactivity
is to some extent species-specific; studies on mice may
be misleading. Caution is appropriate in interpreting anti-
body characterisation studies in gluten ataxia: even appar-
ently positive immunocytochemistry with a cell-surface
pattern of reactivity may not be relevant.
Drawbacks of this study include its performance on
unselected recently diagnosed CD subjects, none of
whom displayed obvious ataxia, and the lack of direct
anti-tissue transglutaminase-6 immunoreactivity test-
ing. Advantages include the short duration of treat-
ment prior to testing (ensuring high titres), the careful
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different species in each of two different methods of
assessing immunoreactivity, and the serendipitous in-
clusion of an identical twin pair.
Methods
Subjects
Eleven subjects with newly-diagnosed coeliac disease were
recruited. Their demographic characteristics were as follows:
M:F = 3:8; mean age 45 ± 20 years (range 19–77); mean time
elapsed between diagnosis and study 5.5 ± 2.9 weeks (range
1.5-11.5). Two subjects (#4 and #5) were identical twins.
Diagnosis was made on small bowel biopsy in all sub-
jects, and in each case confirmatory HLA testing sup-
ported the diagnosis, showing all to be HLA-DQB1*02
positive. In the seven in whom the test results were
available, anti-tissue transglutaminase antibodies IgA
were also positive.
All underwent ICARS (International Cooperative Ataxia
Rating Scale) assessment [21], which has been shown to
have high inter-rater reliability [22]. Mean ICARS score
was 5.5/100 ± 6 (range 2–15). All were within normal
limits of ≤9 [22,23] apart from one subject aged 77 with
pre-existing typical essential tremor at 7.5 Hz; subtracting
this subject’s tremor-contaminated scores reduced his
ICARS score to 5.
For comparison, a convenience sample consisting of
10 healthy, asymptomatic hospital and laboratory workers
and subject’s spouses was utilised, with the following char-
acteristics: M:F 5:5; mean age 33 ± 10 years. All were anti-
tissue transglutaminase IgA-negative.
Sera was collected from CD and healthy control sub-
jects, and stored at −20/-70°C prior to testing. Control
human brain tissue for Western blotting was obtained
from the Victorian Brain Bank Network, Melbourne.
The study was conducted with the approval of the Alfred
Hospital and Monash University Human Research Ethics
Committee (Project Numbers: 69/07 and 2007/0498MC).
ELISA
Serum IgA, IgG- and combined IgA,G,M-class anti-gliadin
titres were measured by an in-house-developed indirect
enzyme-linked immunosorbent assay (ELISA) as previously
described [20]. Briefly, high binding ELISA plates (Greiner)
were coated with 500 ng of non-deamidated gliadin (Vital
Diagnostics). Patient serum was serially diluted and added
to plates in duplicates. Bound antibody was detected with
rabbit anti-human IgA, IgG or IgA,G,M horseradish
peroxidase (HRP)-conjugated antibodies (DAKO, Australia).
Bound antibodies were detected with SigmaFAST OPD sub-
strate (Sigma) and the absorbance was measured using a
multi-well plate reader read at 492 nm. Adjusted optical
densities (ODs) were calculated by subtracting gliadin-
coated wells’ OD values from uncoated wells’ OD values.An anti-GAD ELISA was performed on 9/11 CD pa-
tients by the Royal Melbourne Hospital Pathology ser-
vice, there being insufficient sera available from identical
twins CD4 and CD5 for this assay.
Western blot
Serum samples were tested for the presence of anti-
bodies to cerebellar and cerebral cortical antigens using
a Western blot assay. Cerebellum and cerebral cortex
samples from normal humans and C57BL/6 mice were
homogenised on ice in lysis buffer (20 mM Tris, 5 mM
EDTA, and 1% Nonidet P-40 with a protease inhibitor
cocktail (Roche), pH 7.5) followed by sonication for 15
seconds at 5 watts (Qsonica). Tissue homogenates were
centrifuged at 20,000 g, 4°C for 10 minutes and the
supernatant collected for analysis. Protein concentration
was measured with the microBCA assay (Pierce) using
bovine serum albumin (BSA) as the standard. 500 ug of
total protein (10.9 ug/mm) was separated using a 13%
SDS-PAGE separating gel followed by transfer to a 0.22 um
pore nitrocellulose membrane (Biorad). The membrane
was blocked in 5% skim milk powder in TBS-Tween 20
for 1 hour at room temperature. The membrane was
clamped with a Surfblot 30 channel device (Idea Scien-
tific) and patient or control serum (diluted 1:250, 1:500
or 1:1000), rabbit anti-TG6 (1:200; Abcam) and rabbit
anti-gliadin (1:1000; Sigma) were applied to separate
channels and incubated overnight at 4°C. The membranes
were washed in TBS-Tween-20 for 3 h followed by incuba-
tion with goat anti-human IgG HRP-conjugated antibody
(1:60, 000; Abcam) or swine anti-rabbit-HRP (1:4000;
Dako), as appropriate for the respective primary anti-
bodies, for 1 h. Chemiluminescent detection was per-
formed using the Lightning Fast Plus system (Perkin
Elmer) according to the manufacturer’s instructions.
Immunohistochemistry
Mouse cerebellar sections were obtained from HLA-DQ2
transgenic mice [24] as previously described [20]. The 7 μm
thick sections were deparaffinised and antigens were un-
masked by heating in a microwave with the sections
immersed in 10 mM Tris, 1 mM EDTA, 0.05% v/v Tween
20 buffer, pH 9.0. The sections were blocked for 30 min in
0.1% BSA, 2% goat serum in PBS. Patient or control serum
(1:500), human anti-Hu (neat; Immco; as a positive control
for autoantibodies to Purkinje cells (PCs)), human anti-Yo
(neat; Immco; as a positive control for cytoplasmic-specific
staining of PCs), and mouse anti-calbindin (1:200; Abcam;
as a positive control for Purkinje cell dendrites) were di-
luted in blocking buffer and incubated overnight at 4 C.
The sections were washed in PBS and then fluorescently
labelled with secondary antibodies diluted in blocking buf-
fer; goat anti-human AlexaFuor 488 (1:200; Invitrogen),
and goat anti-mouse AlexaFluor 488 (1:200; Invitrogen) or
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sections were mounted with Vectashield (Vector Labs)
containing DAPI as a nuclear counterstain. For primate
cerebellar sections (Immco Diagnostics) the same staining
protocol was performed, omitting the deparaffinisation and
antigen un-masking steps. Each experiment also included
negative controls in which primary antibodies were omitted.
Immunofluorescent images were taken with an Olympus
BX50 microscope. Images of stained sections were assessed
for cell types independently by a blinded observer, with
respect to positivity above background and pattern of
immunoreactivity.
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